Please Wait...

α CTX-I // Alpha C-Terminal Crosslinked Telopeptide of Type I Collagen

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

In bone, type I collagen constitute 90% of the organic matrix. Markers of bone resorption in serum or urine can be used to assess changes in bone resorption in various bone diseases or under treatment (Naylor and Eastell, 2012). Collagen in bone can be isomerized with racemization of the aspartic residues in the CTX telopeptide. The newly formed collagen is α isomerized and β isomerization occurs with aging (Garnero, 2012). In urine, the ratio between native and isomerized CTX can give an estimate of the extent of type I collagen isomerization in bone tissue (Cloos and Fledelius, 2000). Detection of α isomerized fragment in urine is an indicator of newly formed collagen degradation and can be used for detection of bone metastases or Paget’s disease and follow up of treatments. Detection of β isomerized fragments in urine or serum is an indicator of mature bone collagen degradation, like in osteoporosis.

Different manual or automated sandwich immunoassays for CTX-I with α or β isomerization are validated in Bioclinica Lab for measurement in urine or serum matrix. Results in urine are normalized with values of urine creatinine.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Join Bioclinica in a live #Xtalks webinar 10/31 exploring challenges & benefits of different sourcing models to man… https://t.co/kRYNc1Z3gj
bioclinica (3 hours ago)
Bioclinica contributions toward advancement of #Alzheimer's disease research & therapies showcased in 8 different s… https://t.co/j96UN9568o
bioclinica (9 hours ago)
Bioclinica’s Joby John reflects on the #SCDM2018 Annual Conference & being a part a thriving community of clinical… https://t.co/c70gH5kJo9
bioclinica (Yesterday)
RT @bioclinica: Our own Jeff Heilbraun is in Tokyo nxt wk to lead a discussion at DIA’s Cardiac Safety Workshop in Japan. Jeff will give an…
bioclinica (Yesterday)
RT @Xtalks: Trends in #SitePayments: Insight into How CROs Can Gain a Competitive Edge This webinar will focus on the latest market researc…
bioclinica (Yesterday)
Great connecting w @bioclinica clients Odonate Therapeutics, Eisai, & PCI Biotech, at #ESMO18 #oncology… https://t.co/4wKrLof8e6
bioclinica (Yesterday)

Latest Blogs:

Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner